PMID- 17462498
OWN - NLM
STAT- MEDLINE
DCOM- 20070626
LR  - 20181113
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 68
IP  - 5
DP  - 2007 May
TI  - Donor-recipient combinations of group A and B KIR haplotypes and HLA class I 
      ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell 
      transplantation.
PG  - 309-23
AB  - The influence of donor and recipient killer immunoglobulin-like receptor (KIR) 
      genotype on the outcome of hematopoietic cell transplantation between human 
      leukocyte antigen (HLA)-matched siblings was investigated. Transplants were 
      divided into four groups according to the combination of group A and B KIR 
      haplotypes in the transplant donor and recipient. Overall survival of myeloid 
      patients varied with KIR genotype combination. Best survival was associated with 
      the donor lacking and the recipient having group B KIR haplotypes; poorest 
      survival was associated with the donor having and the recipient lacking group B 
      KIR haplotypes. The latter combination was also associated with increased relapse 
      and acute graft-versus-host disease (GVHD). However, its detrimental effects were 
      seen only for transplants where the recipient and donor were homozygous for the 
      C1 KIR ligand and therefore lacked the C2 ligand. Presence of the Bw4 ligand was 
      also associated with increased acute GVHD. In contrast presence of both KIR3DL1 
      and its cognate Bw4 ligand was associated with decreased nonrelapse mortality. 
      Analysis of the KIR genes individually revealed KIR2DS3 as a protective factor 
      for chronic GVHD. The results suggest how simple assessments of KIR genotype 
      might inform the selection of donors for hematopoietic cell transplantation.
FAU - McQueen, Karina L
AU  - McQueen KL
AD  - Department of Structural Biology, Stanford University School of Medicine, 
      Stanford, CA, USA.
FAU - Dorighi, Kristel M
AU  - Dorighi KM
FAU - Guethlein, Lisbeth A
AU  - Guethlein LA
FAU - Wong, Ruby
AU  - Wong R
FAU - Sanjanwala, Bharati
AU  - Sanjanwala B
FAU - Parham, Peter
AU  - Parham P
LA  - eng
GR  - P01 CA049605/CA/NCI NIH HHS/United States
GR  - CA49605/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070312
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (KIR3DL1 protein, human)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR3DL1)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Gene Frequency
MH  - Genotype
MH  - Graft vs Host Disease/genetics
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens/genetics
MH  - HLA-C Antigens/genetics
MH  - Haplotypes
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Histocompatibility Testing/statistics & numerical data
MH  - Humans
MH  - Leukemia/genetics/immunology/*surgery
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Receptors, Immunologic/*genetics
MH  - Receptors, KIR
MH  - Receptors, KIR3DL1
MH  - Risk Factors
MH  - Siblings
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC1937576
MID - NIHMS22916
EDAT- 2007/04/28 09:00
MHDA- 2007/06/27 09:00
PMCR- 2008/05/01
CRDT- 2007/04/28 09:00
PHST- 2006/09/14 00:00 [received]
PHST- 2007/01/17 00:00 [revised]
PHST- 2007/01/23 00:00 [accepted]
PHST- 2007/04/28 09:00 [pubmed]
PHST- 2007/06/27 09:00 [medline]
PHST- 2007/04/28 09:00 [entrez]
PHST- 2008/05/01 00:00 [pmc-release]
AID - S0198-8859(07)00028-6 [pii]
AID - 10.1016/j.humimm.2007.01.019 [doi]
PST - ppublish
SO  - Hum Immunol. 2007 May;68(5):309-23. doi: 10.1016/j.humimm.2007.01.019. Epub 2007 
      Mar 12.